Litigation Details for ACADIA Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2020)

ACADIA Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2020)

Docket	1:20-cv-00986	Date Filed	2020-07-24
Court	District Court, D. Delaware	Date Terminated	2024-05-07
Cause	35:271 Patent Infringement	Assigned To	Gregory B. Williams
Jury Demand	None	Referred To
Patents	10,449,185; 10,646,480; 7,601,740; 7,659,285; 7,732,615; 7,923,564
Link to Docket	External link to docket

Details for ACADIA Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-07-24				External link to document
2020-07-24	14	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 7,659,285 B2 ;US 7,923,564 …July 2020 7 May 2024 1:20-cv-00986 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-07-24	4	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,601,740 ;7,732,615 ;10,449,185 ;10,646,480… 24 July 2020 1:20-cv-00986 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation summary and analysis for: ACADIA Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2020)

Last updated: July 1, 2026

ACADIA v. Teva (1:20-cv-00986) Litigation Summary: Patent Claims, Posture, and Commercial Impact for Nuplazid® (pimavanserin)

ACADIA Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., Civil Action No. 1:20-cv-00986, is a Hatch-Waxman patent infringement dispute tied to Teva’s effort to market a generic version of ACADIA’s antipsychotic for Parkinson’s disease psychosis, Nuplazid® (pimavanserin). The case is procedurally postured as an ANDA paragraph IV-type dispute in the federal court system, with the core business question focused on whether Teva can launch at the end of the relevant Orange Book and exclusivity timelines or whether ACADIA’s asserted patents block launch through injunction or settlement.

What follows is a complete litigation summary and analysis only where the underlying case record details are determinable from a provided docket. No docket content was provided in the request. Under the operating constraints, an incomplete or non-verifiable answer is not produced.